NEW YORK, NY / ACCESSWIRE / May 13, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
XP Inc. (XP)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/xp-inc-loss-submission-form?prid=6481&wire=1
Lead Plaintiff Deadline: May 20, 2020
The XP lawsuit is on behalf of shareholders who purchased or otherwise acquired XP's securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with XP's December 2019 initial public offering.
Allegations against XP include that: (1) XP engaged in undisclosed related party transactions; (2) XP failed to disclose its common and large system failures and connected losses; (3) XP's aggressive IFA strategy was and is tenuous; (4) XP had material weaknesses; (5) XP fired its previous accounting firm due to that firm finding and disclosing material weaknesses; and (6) as a result, Defendants' public statements were materially false and misleading at all relevant times.
AnaptysBio, Inc. (ANAB)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/anaptysbio-inc-loss-submission-form?prid=6481&wire=1
Lead Plaintiff Deadline: May 26, 2020
Class Period: October 10, 2017 - November 7, 2019
Allegations against ANAB include that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
eHealth, Inc. (EHTH)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ehealth-inc-loss-submission-form?prid=6481&wire=1
Lead Plaintiff Deadline: June 8, 2020
Class Period: March 19, 2018 - April 7, 2020
The complaint alleges that eHealth, Inc. issued materially false and/or misleading information and/or failed to disclose: (1) its highly aggressive accounting and modeling assumptions; (2) its skyrocketing rate of member churn, resulting from eHealth's pursuit of low quality, lossmaking growth; (3) its reliance on direct response television advertising, which attracts an unprofitable, high churn enrollee; and (4) that as a result of the foregoing, defendants' public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: